Improved prediction of fellow-eye response in one-eye trials using multiple intraocular pressure measurements

Abstract

Using multiple post-treatment IOP measurements may improve the prediction of a fellow eye's response to glaucoma medication in one-eye trials.

Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension

“…In that study, they claimed that multiple IOP measurements on different days after treatment may be required to ascertain the average IOP responsiveness of the treated eye. Therefore, the number of IOP measurements to be evaluated in this study was determined according to the report by Wakabayashi et al 19. They described that two IOP measurements rather than a single one, especially in the post-treatment period, may improve the prediction of a fellow eye's response to glaucoma medication in a one-eye trial.…”

Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects

“…IOP reduction after glaucoma medication is caused not only by true pharmacological effects, but also by spontaneous IOP fluctuations. Therefore, one-eye trials, which are supposed to reveal the true pharmacological effects by subtracting the IOP changes of the non-treated eye from that of the treated eye, are recommended [18].…”